Literature DB >> 7016383

Pharmacokinetics of drug overdose.

J Rosenberg, N L Benowitz, S Pond.   

Abstract

Pharmacokinetics of drugs taken in overdose may differ from those observed following therapeutic doses. Differences are due both to dose-dependent changes and to effects of drugs or pathophysiological consequences of the overdose on kinetics. Dose-dependent changes in rate and extent of absorption, bioavailability (saturation of first-pass metabolism), distribution (saturation of protein binding sites) and metabolism are discussed. Gastrointestinal motility is affected both by specific drug actions, such as delayed gastric emptying by anticholinergic drugs, and by general nervous system depression caused by many drugs. Drug-induced circulatory insufficiency may retard tissue distribution and reduce clearance. Disturbances in blood and urine pH may alter distribution and clearance of weak acids and bases. Drug-induced renal or hepatic failure can significantly decrease clearance. Hypothermia is a common complication of drug overdose and might retard distribution and also reduce clearance. The data concerning pharmacokinetics during overdose are usually incomplete and difficult to interpret. Doses and times of ingestion are uncertain, duration of blood and urine sampling is often inadequate to distinguish absorption from distribution and elimination phases, active metabolites are not measured, protein binding is not determined and clinical features of patients not adequately described. We have, however, reviewed available data for salicylate, paracetamol (acetaminophen), barbiturates, ethchlorvynol, glutethimide, chloral hydrate, tricyclic antidepressants, lithium, phenytoin, ethanol, theophylline, digoxin, amphetamine and phencyclidine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7016383     DOI: 10.2165/00003088-198106030-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  167 in total

Review 1.  Salicylate intoxication.

Authors:  J B Hill
Journal:  N Engl J Med       Date:  1973-05-24       Impact factor: 91.245

2.  Amphetamine metabolism in amphetamine psychosis.

Authors:  E Anggård; L E Jönsson; A L Hogmark; L M Gunne
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

3.  Absorption kinetics of aspirin in man following oral administration of an aqueous solution.

Authors:  M Rowland; S Riegelman; P A Harris; S D Sholkoff
Journal:  J Pharm Sci       Date:  1972-03       Impact factor: 3.534

4.  Urine pH and salicylate therapy.

Authors:  G Levy; J R Leonards
Journal:  JAMA       Date:  1971-07-05       Impact factor: 56.272

5.  Acute glutethimide poisoning. Conservative management of 31 patients.

Authors:  N Wright; P Roscoe
Journal:  JAMA       Date:  1970-11-30       Impact factor: 56.272

6.  Acute massive chloral hydrate intoxication treated with hemodialysis: a clinical pharmacokinetic analysis.

Authors:  N E Stalker; J G Gambertoglio; C J Fukumitsu; J L Naughton; L Z Benet
Journal:  J Clin Pharmacol       Date:  1978 Feb-Mar       Impact factor: 3.126

7.  Identification and activity of the hydroxy metabolite that accumulates in the plasma of humans intoxicated with glutethimide.

Authors:  J J Ambre; L J Fischer
Journal:  Drug Metab Dispos       Date:  1974 Mar-Apr       Impact factor: 3.922

8.  Pharmacokinetics of salicylate elimination in man.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1965-07       Impact factor: 3.534

9.  Kinetics of salicylate elimination by anephric patients.

Authors:  D T Lowenthal; W A Briggs; G Levy
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

10.  Permanent neurological sequelae despite haemodialysis for lithium intoxication.

Authors:  B Von Hartitzsch; N A Hoenich; R J Leigh; R Wilkinson; T H Frost; A Weddel; G A Posen
Journal:  Br Med J       Date:  1972-12-30
View more
  9 in total

1.  Non-linear kinetics of 4-methylpyrazole in healthy human subjects.

Authors:  D Jacobsen; S K Barron; C S Sebastian; R Blomstrand; K E McMartin
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Role of repeated oral doses of activated charcoal in clinical toxicology.

Authors:  S M Pond
Journal:  Med Toxicol       Date:  1986 Jan-Feb

Review 3.  Clinical toxicology.

Authors:  J A Vale
Journal:  Postgrad Med J       Date:  1993-01       Impact factor: 2.401

Review 4.  Clinical pharmacokinetics of oral activated charcoal in acute intoxications.

Authors:  P J Neuvonen
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

Review 5.  Management of the critically poisoned patient.

Authors:  Jennifer S Boyle; Laura K Bechtel; Christopher P Holstege
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2009-06-29       Impact factor: 2.953

Review 6.  Pharmacokinetic considerations in clinical toxicology: clinical applications.

Authors:  Darren M Roberts; Nick A Buckley
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Oral activated charcoal in the treatment of intoxications. Role of single and repeated doses.

Authors:  P J Neuvonen; K T Olkkola
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jan-Dec

Review 8.  The Individualized Management Approach for Acute Poisoning.

Authors:  Muneera Al-Jelaify; Suliman AlHomidah
Journal:  Adv Pharmacol Pharm Sci       Date:  2021-05-12

9.  Poisoned patients as potential organ donors: postal survey of transplant centres and intensive care units.

Authors:  David Michael Wood; Paul Ivor Dargan; Alison Linda Jones
Journal:  Crit Care       Date:  2003-03-06       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.